Q32 Bio Inc (QTTB)

$4.73 +0.23 (5.11%)
Market Cap 55.37M
Revenue (ttm) 0.00
Net Income (ttm) -47.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.61
Volume 172,200
Avg Vol 172,214
Day's Range N/A - N/A
Shares Out 12.30M
Stochastic %K 94%
Beta 0.16
Analysts Sell
Price Target $15.00

Company Profile

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic derm...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 999 0232
Address:
830 Winter Street, Waltham, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 25 at 8:28 PM
$QTTB RSI: 60.91, MACD: 0.2353 Vol: 0.32, MA20: 4.13, MA50: 3.71 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
RealVictor
RealVictor Feb. 25 at 8:13 PM
>> $FLYE $AHMA $CNCK $QTTB <<
0 · Reply
LunarPanda1
LunarPanda1 Feb. 24 at 12:50 AM
*@SqueezeSharkie is operating on a whole different level, easily ahead of 90% of the traders on this platform. *If you’re not paying attention yet, you’re missing out. Go give him a follow. It’s completely free and only takes a second 💎 $SHIP $IPDN $QTTB $AXTI <>^
0 · Reply
OnyxPredator
OnyxPredator Feb. 23 at 3:11 PM
$LSH $AGBK $MAC $QTTB >>>>
0 · Reply
Gtrading1234
Gtrading1234 Feb. 22 at 8:22 AM
$QTTB
0 · Reply
No_Face_character
No_Face_character Feb. 21 at 6:57 PM
$QTTB
0 · Reply
No_Face_character
No_Face_character Feb. 21 at 6:41 PM
$QTTB interesting gap on the chart
0 · Reply
No_Face_character
No_Face_character Feb. 21 at 6:40 PM
$QTTB appears to be highest close since 12/11/2024
0 · Reply
No_Face_character
No_Face_character Feb. 21 at 6:37 PM
$QTTB as mentioned by @YouVSYou
0 · Reply
No_Face_character
No_Face_character Feb. 21 at 6:34 PM
$QTTB
0 · Reply
Latest News on QTTB
Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 18, 2026, 6:59 AM EST - 7 days ago

Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Q32 Bio Announces $10.5 Million Registered Direct Offering

Feb 17, 2026, 6:59 AM EST - 8 days ago

Q32 Bio Announces $10.5 Million Registered Direct Offering

Dow Dips 200 Points; Q32 Bio Shares Jump

Dec 1, 2025, 9:58 AM EST - 3 months ago

Dow Dips 200 Points; Q32 Bio Shares Jump

Why Is Small-Cap Q32 Bio Stock Soaring On Monday?

Dec 1, 2025, 9:43 AM EST - 3 months ago

Why Is Small-Cap Q32 Bio Stock Soaring On Monday?

Q32 Bio Sells Complement Inhibitor ADX-097

Dec 1, 2025, 7:00 AM EST - 3 months ago

Q32 Bio Sells Complement Inhibitor ADX-097

AKBA

Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 6:59 AM EST - 3 months ago

Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

Oct 21, 2025, 6:59 AM EDT - 4 months ago

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference

Aug 28, 2025, 6:59 AM EDT - 6 months ago

Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference

Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 6:59 AM EDT - 7 months ago

Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

Jun 25, 2025, 6:59 AM EDT - 8 months ago

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 6:59 AM EDT - 10 months ago

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

Apr 30, 2025, 6:59 AM EDT - 10 months ago

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

Apr 16, 2025, 6:59 AM EDT - 11 months ago

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Mar 11, 2025, 6:59 AM EDT - 1 year ago

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

Mar 8, 2025, 11:00 AM EST - 1 year ago

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

Feb 28, 2025, 9:00 AM EST - 1 year ago

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

Q32 Bio to Participate in Upcoming March Investor Conferences

Feb 26, 2025, 6:59 AM EST - 1 year ago

Q32 Bio to Participate in Upcoming March Investor Conferences

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Feb 10, 2025, 4:05 PM EST - 1 year ago

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 4:05 PM EST - 1 year ago

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Why Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?

Dec 11, 2024, 11:32 AM EST - 1 year ago

Why Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Dec 10, 2024, 4:05 PM EST - 1 year ago

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 6:59 AM EST - 1 year ago

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Nov 5, 2024, 6:59 AM EST - 1 year ago

Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Oct 14, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Q32 Bio to Participate in Upcoming September Investor Conferences

Aug 29, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio to Participate in Upcoming September Investor Conferences

Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097

Aug 29, 2024, 3:40 AM EDT - 1 year ago

Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097

8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%

Aug 1, 2024, 4:54 PM EDT - 1 year ago

8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%

EBS HE HUMA SAVA SERV

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

Jul 9, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

Q32 Bio Joins Russell 3000® Index

Jul 1, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio Joins Russell 3000® Index

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

Apr 3, 2024, 7:00 AM EDT - 2 years ago

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million

Mar 25, 2024, 4:15 PM EDT - 2 years ago

Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million

OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 25 at 8:28 PM
$QTTB RSI: 60.91, MACD: 0.2353 Vol: 0.32, MA20: 4.13, MA50: 3.71 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
RealVictor
RealVictor Feb. 25 at 8:13 PM
>> $FLYE $AHMA $CNCK $QTTB <<
0 · Reply
LunarPanda1
LunarPanda1 Feb. 24 at 12:50 AM
*@SqueezeSharkie is operating on a whole different level, easily ahead of 90% of the traders on this platform. *If you’re not paying attention yet, you’re missing out. Go give him a follow. It’s completely free and only takes a second 💎 $SHIP $IPDN $QTTB $AXTI <>^
0 · Reply
OnyxPredator
OnyxPredator Feb. 23 at 3:11 PM
$LSH $AGBK $MAC $QTTB >>>>
0 · Reply
Gtrading1234
Gtrading1234 Feb. 22 at 8:22 AM
$QTTB
0 · Reply
No_Face_character
No_Face_character Feb. 21 at 6:57 PM
$QTTB
0 · Reply
No_Face_character
No_Face_character Feb. 21 at 6:41 PM
$QTTB interesting gap on the chart
0 · Reply
No_Face_character
No_Face_character Feb. 21 at 6:40 PM
$QTTB appears to be highest close since 12/11/2024
0 · Reply
No_Face_character
No_Face_character Feb. 21 at 6:37 PM
$QTTB as mentioned by @YouVSYou
0 · Reply
No_Face_character
No_Face_character Feb. 21 at 6:34 PM
$QTTB
0 · Reply
scoon42
scoon42 Feb. 20 at 8:45 PM
$QTTB 1year target $15
0 · Reply
McLarkin
McLarkin Feb. 20 at 8:07 PM
$QTTB have we another NEKTAR? Maybe... fascinating microcap.... the AA readout will be fun....
1 · Reply
Dipps
Dipps Feb. 20 at 9:18 AM
$QTTB https://www.stocktitan.net/news/QTTB/q32-bio-to-participate-in-the-oppenheimer-36th-annual-healthcare-ctt5cfwg57qu.html
0 · Reply
YouVSYou
YouVSYou Feb. 19 at 10:02 PM
$QTTB Point72 2.06M 9.9% https://www.sec.gov/Archives/edgar/data/1603466/000090266426001202/xslSCHEDULE_13G_X01/primary_doc.xml
1 · Reply
KatherineBarnett501
KatherineBarnett501 Feb. 18 at 1:34 PM
$QTTB Community bank with stable earnings.
0 · Reply
Dipps
Dipps Feb. 17 at 2:13 PM
$QTTB https://www.prnewswire.com/news-releases/q32-bio-announces-10-5-million-registered-direct-offering-302689038.html
0 · Reply
MorphismMogul
MorphismMogul Feb. 17 at 12:15 PM
$QTTB Obscure micro-cap; minimal information, extreme caution.
0 · Reply
FlowTactix
FlowTactix Feb. 17 at 9:28 AM
$QTTB Obscure micro-cap; likely illiquid
0 · Reply
Stef_DL
Stef_DL Feb. 12 at 8:16 PM
$QTTB This stonk is so strange. 10% down yesterday and now 12% up on no news whatsoever 😅. I take it as
1 · Reply
ffienimi
ffienimi Feb. 11 at 6:06 PM
$QTTB why???
0 · Reply
Dipps
Dipps Feb. 11 at 7:37 AM
$QTTB from Dec, interesting read with an analyst price target of $15! https://ts2.tech/en/q32-bio-qttb-stock-explodes-after-592-million-akebia-deal-latest-news-analyst-targets-and-2027-outlook/
0 · Reply
Justjohnn
Justjohnn Feb. 10 at 6:52 PM
$QTTB News would be welcomed at this point
0 · Reply